AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21856006 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoroquinolone antibiotics (gatifloxacin 0.3%, moxifloxacin 0.5%, ofloxacin 0.3%)
Number of subjects: 24
Study 21856006 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin 1%
Number of subjects: 24
Study 21856006 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated fellow eye)
Number of subjects: 24
Study 19101268 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary shunt
Number of subjects: 56
Study 19101268 — intervention group
Group type: COMPARATOR
Intervention: Occlusive snaring (Control)
Number of subjects: 56
Study 19101268 — intervention group
Group type: COMPARATOR
Intervention: Both groups (shunted and nonshunted)
Number of subjects: 56
Study 18705930 — intervention group
Group type: EXPERIMENTAL
Intervention: STRokE DOC telemedicine
Number of subjects: 400
Study 18705930 — intervention group
Group type: COMPARATOR
Intervention: Telephone consultations
Number of subjects: 400
Study 15334790 — intervention group
Group type: EXPERIMENTAL
Intervention: Repaglinide plus acarbose (2 mg repaglinide 15 min before breakfast followed by 100 mg acarbose with breakfast)
Number of subjects: 40
Study 15334790 — intervention group
Group type: COMPARATOR
Intervention: Repaglinide alone (2 mg)
Number of subjects: 40
Study 15334790 — intervention group
Group type: EXPERIMENTAL
Intervention: Repaglinide plus acarbose
Number of subjects: 40
Study 15334790 — intervention group
Group type: COMPARATOR
Intervention: Repaglinide alone
Number of subjects: 40
Study 11524040 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 i.u. of oral alpha-tocopherol daily for 8 weeks
Number of subjects: 70
Study 11524040 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 9988942 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem 120 mg/day
Number of subjects: 94
Study 9988942 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem 180 mg/day
Number of subjects: 94
Study 9988942 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem 240 mg/day
Number of subjects: 94
Study 9988942 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release diltiazem (120 mg twice a day)
Number of subjects: 94
Study 9988942 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 94
Study 7599713 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision tree
Number of subjects: 0
Study 2082209 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxiracetam treatment
Number of subjects: 36
Study 2082209 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 36
Study 347606 — intervention group
Group type: EXPERIMENTAL
Intervention: Taurolin administered intraperitoneally
Number of subjects: 0
Study 347606 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 30768758 — intervention group
Group type: EXPERIMENTAL
Intervention: AT + RT
Number of subjects: 137
Study 30768758 — intervention group
Group type: EXPERIMENTAL
Intervention: RT
Number of subjects: 137
Study 30768758 — intervention group
Group type: EXPERIMENTAL
Intervention: AT
Number of subjects: 137
Study 30768758 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 137
Study 30768758 — intervention group
Group type: EXPERIMENTAL
Intervention: AT, RT, AT + RT
Number of subjects: 137
Study 28224745 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplemental oxygen at a flow rate of 2 l/min
Number of subjects: 443
Study 28224745 — intervention group
Group type: COMPARATOR
Intervention: Sham supplementation by nasal cannula
Number of subjects: 443
Study 25211175 — intervention group
Group type: EXPERIMENTAL
Intervention: Butorphanol
Number of subjects: 0
Study 25211175 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 24229373 — intervention group
Group type: EXPERIMENTAL
Intervention: Community Development Teams (CDTs)
Number of subjects: 176
Study 24229373 — intervention group
Group type: COMPARATOR
Intervention: Standard condition
Number of subjects: 176
Study 22303707 — intervention group
Group type: EXPERIMENTAL
Intervention: Unblocking meridians and Du-channel massage combined with rehabilitation training
Number of subjects: 80
Study 22303707 — intervention group
Group type: COMPARATOR
Intervention: Bobath technique (control group)
Number of subjects: 80
Study 20084571 — intervention group
Group type: COMPARATOR
Intervention: Midazolam
Number of subjects: 74
Study 20084571 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam plus meperidine
Number of subjects: 74
Study 16707516 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide treatment
Number of subjects: 1128
Study 16707516 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher FEV1 % predicted
Number of subjects: 1128
Study 16707516 — intervention group
Group type: EXPERIMENTAL
Intervention: Increase in number of cigarettes smoked
Number of subjects: 1128
Study 16707516 — intervention group
Group type: EXPERIMENTAL
Intervention: Annual FEV1 improvement
Number of subjects: 1128
Study 15225146 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducation
Number of subjects: 37
Study 15225146 — intervention group
Group type: COMPARATOR
Intervention: Control (non-structured intervention)
Number of subjects: 37
Study 11423597 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer generated ECG reports
Number of subjects: 10
Study 11423597 — intervention group
Group type: COMPARATOR
Intervention: No computer generated ECG reports (control)
Number of subjects: 10
Study 9403364 — intervention group
Group type: EXPERIMENTAL
Intervention: Apomorphine (continuous subcutaneous infusion for three weeks)
Number of subjects: 6
Study 9403364 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 8197894 — intervention group
Group type: EXPERIMENTAL
Intervention: Paired flavor consumed immediately as malaise began to decline (short-delay group)
Number of subjects: 45
Study 8197894 — intervention group
Group type: COMPARATOR
Intervention: Unpaired flavor consumed the morning after each session
Number of subjects: 45
Study 8197894 — intervention group
Group type: EXPERIMENTAL
Intervention: Paired flavor consumed when malaise had completely diminished (long-delay group)
Number of subjects: 45
Study 3134446 — intervention group
Group type: EXPERIMENTAL
Intervention: Dimethicone
Number of subjects: 0
Study 3134446 — intervention group
Group type: EXPERIMENTAL
Intervention: Senna extract
Number of subjects: 0
Study 3134446 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of dimethicone and senna extract
Number of subjects: 0
Study 3134446 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31291470 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal transplant recipients (RTRs)
Number of subjects: 4261
Study 31291470 — intervention group
Group type: COMPARATOR
Intervention: Non-transplanted comparison cohort (non-RTRs)
Number of subjects: 4261
Study 30376796 — intervention group
Group type: EXPERIMENTAL
Intervention: Bench-top simulator (group E1)
Number of subjects: 100
Study 30376796 — intervention group
Group type: COMPARATOR
Intervention: Control group (group E5)
Number of subjects: 100
Study 27671627 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone enanthate
Number of subjects: 40
Study 27671627 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 26634701 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (28 villages); rapid testing of stored maize for aflatoxin, replacement of contaminated maize, and access to low-aflatoxin maize at local shops.
Number of subjects: 1223
Study 26634701 — intervention group
Group type: COMPARATOR
Intervention: Control group (28 villages); no intervention regarding aflatoxin exposure.
Number of subjects: 1223
Study 22867539 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol 1 g and ketorolac 20 mg intravenously
Number of subjects: 0
Study 22867539 — intervention group
Group type: EXPERIMENTAL
Intervention: UVB irradiation
Number of subjects: 0
Study 20828989 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioabsorbable osteosynthesis (26 patients in bilateral sagittal ramus osteotomy, 17 patients in Le Fort I osteotomy, 8 patients in bimaxillary osteotomy)
Number of subjects: 101
Study 20828989 — intervention group
Group type: COMPARATOR
Intervention: Titanium osteosynthesis (29 patients in bilateral sagittal ramus osteotomy, 11 patients in Le Fort I osteotomy, 10 patients in bimaxillary osteotomy)
Number of subjects: 101
Study 18809631 — intervention group
Group type: EXPERIMENTAL
Intervention: 12.5 mg alogliptin
Number of subjects: 329
Study 18809631 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg alogliptin
Number of subjects: 329
Study 18809631 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 329
Study 18809631 — intervention group
Group type: EXPERIMENTAL
Intervention: Alogliptin (both doses)
Number of subjects: 329
Study 18809631 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 329
Study 15713945 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous parecoxib for at least 3 days followed by oral valdecoxib through day 10
Number of subjects: 1671
Study 15713945 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous placebo followed by oral valdecoxib
Number of subjects: 1671
Study 15713945 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 10 days
Number of subjects: 1671
Study 12660054 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin 300 mg orally twice daily for 5 days
Number of subjects: 494
Study 12660054 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 494
Study 10752988 — intervention group
Group type: EXPERIMENTAL
Intervention: INF combined with hydroxyurea
Number of subjects: 143
Study 10752988 — intervention group
Group type: COMPARATOR
Intervention: INF combined with cytarabine
Number of subjects: 143
Study 8783785 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine GITS
Number of subjects: 36
Study 8783785 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide (HCTZ)
Number of subjects: 36
Study 6730944 — intervention group
Group type: EXPERIMENTAL
Intervention: Nova-T
Number of subjects: 331
Study 6730944 — intervention group
Group type: COMPARATOR
Intervention: Copper-T 200
Number of subjects: 331
Study 31842809 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (schools receiving consumables, support kits, and structured tools)
Number of subjects: 20
Study 31842809 — intervention group
Group type: COMPARATOR
Intervention: Control group (schools not receiving the intervention)
Number of subjects: 20
Study 29558323 — intervention group
Group type: EXPERIMENTAL
Intervention: Chicory leaf methanolic extract capsule (1 gram, twice daily for 8 weeks)
Number of subjects: 40
Study 29558323 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsule (1 gram wheat flour, twice daily for 8 weeks)
Number of subjects: 40
Study 26166797 — intervention group
Group type: EXPERIMENTAL
Intervention: Aflibercept therapy
Number of subjects: 19
Study 26166797 — intervention group
Group type: COMPARATOR
Intervention: Ranibizumab therapy
Number of subjects: 19
Study 24281283 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS
Number of subjects: 41
Study 24281283 — intervention group
Group type: COMPARATOR
Intervention: Cathodal tDCS
Number of subjects: 41
Study 21193289 — intervention group
Group type: EXPERIMENTAL
Intervention: Aquarobic exercise program
Number of subjects: 0
Study 19276994 — intervention group
Group type: EXPERIMENTAL
Intervention: Crossed pin fixation (group A)
Number of subjects: 40
Study 19276994 — intervention group
Group type: COMPARATOR
Intervention: Lateral only pin fixation (group B)
Number of subjects: 40
Study 17587393 — intervention group
Group type: EXPERIMENTAL
Intervention: Nateglinide plus metformin
Number of subjects: 262
Study 17587393 — intervention group
Group type: COMPARATOR
Intervention: Gliclazide plus metformin
Number of subjects: 262
Study 15125551 — intervention group
Group type: EXPERIMENTAL
Intervention: Insuflon (subcutaneous indwelling catheter)
Number of subjects: 20
Study 15125551 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous injections
Number of subjects: 20
Study 11453888 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydrocodeine (DHC) 90 mg
Number of subjects: 10
Study 11453888 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 9877014 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam (1.2 mg PO)
Number of subjects: 108
Study 9877014 — intervention group
Group type: COMPARATOR
Intervention: Scopolamine (0.3, 0.6 mg SC)
Number of subjects: 108
Study 9877014 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam (2 mg PO)
Number of subjects: 108
Study 9877014 — intervention group
Group type: COMPARATOR
Intervention: Flumazenil (2 mg IV)
Number of subjects: 108
Study 9877014 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 108
Study 8113065 — intervention group
Group type: EXPERIMENTAL
Intervention: CATCH family intervention (home-based curricula and Family Fun Nights focusing on healthier eating and increased physical activity)
Number of subjects: 28
Study 8113065 — intervention group
Group type: EXPERIMENTAL
Intervention: CATCH family intervention
Number of subjects: 28
Study 8113065 — intervention group
Group type: COMPARATOR
Intervention: Control schools (no family intervention)
Number of subjects: 28
Study 3257300 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical stimulation with a duty-cycle ratio of 1:1
Number of subjects: 18
Study 3257300 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical stimulation with a duty-cycle ratio of 1:3
Number of subjects: 18
Study 3257300 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical stimulation with a duty-cycle ratio of 1:5
Number of subjects: 18
Study 3257300 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical stimulation with a duty-cycle ratio of 1:1, 1:3, and 1:5
Number of subjects: 18
Study 30061156 — intervention group
Group type: EXPERIMENTAL
Intervention: Silent Infarct Transfusion (SIT) Trial intervention
Number of subjects: 286
Study 30061156 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline infarct volume and reticulocyte count
Number of subjects: 286
Study 27933574 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily supplementation of 400 mg of magnesium
Number of subjects: 100
Study 27933574 — intervention group
Group type: COMPARATOR
Intervention: Control group (no magnesium supplementation)
Number of subjects: 100
Study 24806747 — intervention group
Group type: EXPERIMENTAL
Intervention: Niaspan(®) (2 g/day)
Number of subjects: 20
Study 24806747 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 22907079 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonfat milk (500 ml daily for 2 weeks)
Number of subjects: 14
Study 22907079 — intervention group
Group type: COMPARATOR
Intervention: Whole milk (500 ml daily for 2 weeks)
Number of subjects: 14
Study 20381820 — intervention group
Group type: EXPERIMENTAL
Intervention: Statins
Number of subjects: 774
Study 17704866 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent sequential compression (ISC) applied to lower extremities (Group II)
Number of subjects: 60
Study 17704866 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group I)
Number of subjects: 60
Study 17177907 — intervention group
Group type: EXPERIMENTAL
Intervention: Wives who used religious coping along with their husbands (group 3)
Number of subjects: 101
Study 17177907 — intervention group
Group type: COMPARATOR
Intervention: Wives who used religious coping while their husbands did not (group 2)
Number of subjects: 101
Study 14676664 — intervention group
Group type: EXPERIMENTAL
Intervention: Suprapubic catheter drain after bladder repair
Number of subjects: 42
Study 14676664 — intervention group
Group type: COMPARATOR
Intervention: Urethral catheter alone
Number of subjects: 42
Study 12768736 — intervention group
Group type: EXPERIMENTAL
Intervention: HBO combined with medical treatment (treatment group)
Number of subjects: 60
Study 12768736 — intervention group
Group type: COMPARATOR
Intervention: HBO only (control group)
Number of subjects: 60
Study 8972649 — intervention group
Group type: EXPERIMENTAL
Intervention: MR angiography
Number of subjects: 50
Study 8972649 — intervention group
Group type: COMPARATOR
Intervention: Spin-echo MR imaging
Number of subjects: 50
Study 1292233 — intervention group
Group type: EXPERIMENTAL
Intervention: Obsidane
Number of subjects: 0
Study 1292233 — intervention group
Group type: EXPERIMENTAL
Intervention: Sydnopharm
Number of subjects: 0
Study 6366151 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythrocyte sedimentation rate (ESR)
Number of subjects: 676
Study 6366151 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence or absence of systemic symptoms
Number of subjects: 676
Study 6366151 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of ESR and systemic symptoms
Number of subjects: 676
Study 30667317 — intervention group
Group type: EXPERIMENTAL
Intervention: DE iMAR Mono+
Number of subjects: 20
Study 30667317 — intervention group
Group type: EXPERIMENTAL
Intervention: DE iMAR
Number of subjects: 20
Study 30667317 — intervention group
Group type: EXPERIMENTAL
Intervention: DE Mono+
Number of subjects: 20
Study 30667317 — intervention group
Group type: COMPARATOR
Intervention: Original DE mixed images
Number of subjects: 20
Study 30441954 — intervention group
Group type: EXPERIMENTAL
Intervention: faUUT
Number of subjects: 838
Study 30441954 — intervention group
Group type: COMPARATOR
Intervention: inUUT
Number of subjects: 838
Study 27128667 — intervention group
Group type: EXPERIMENTAL
Intervention: Loaded breathing (six breaths per min, 18 cm H2O)
Number of subjects: 30
Study 27128667 — intervention group
Group type: EXPERIMENTAL
Intervention: Unloaded breathing (six breaths per min, no load)
Number of subjects: 30
Study 27128667 — intervention group
Group type: COMPARATOR
Intervention: Control (normal breathing)
Number of subjects: 30
Study 27128667 — intervention group
Group type: EXPERIMENTAL
Intervention: Loaded breathing
Number of subjects: 30
Study 27128667 — intervention group
Group type: EXPERIMENTAL
Intervention: Unloaded breathing
Number of subjects: 30
Study 27128667 — intervention group
Group type: EXPERIMENTAL
Intervention: Loaded breathing and Unloaded breathing
Number of subjects: 30
Study 25327394 — intervention group
Group type: EXPERIMENTAL
Intervention: Oligofructose (8 g/d for ages 7-11 years and 15 g/d for ages 12-18 years) for 12 weeks
Number of subjects: 97
Study 25327394 — intervention group
Group type: COMPARATOR
Intervention: Placebo (maltodextrin) for 12 weeks
Number of subjects: 97
Study 25327394 — intervention group
Group type: EXPERIMENTAL
Intervention: Oligofructose
Number of subjects: 97
Study 25327394 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 97
Study 22037844 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical interventions
Number of subjects: 157
Study 22037844 — intervention group
Group type: COMPARATOR
Intervention: Non-medical interventions
Number of subjects: 157
Study 20467874 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength training program for 10 weeks
Number of subjects: 15
Study 20467874 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute strength training session
Number of subjects: 15
Study 20467874 — intervention group
Group type: COMPARATOR
Intervention: Control group (physically inactive)
Number of subjects: 15
Study 18020845 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-assisted intervention
Number of subjects: 866
Study 18020845 — intervention group
Group type: COMPARATOR
Intervention: Computer-based control condition
Number of subjects: 866
Study 16817786 — intervention group
Group type: EXPERIMENTAL
Intervention: Half-dose of nafamostat mesilate (NM)
Number of subjects: 4
Study 16817786 — intervention group
Group type: COMPARATOR
Intervention: No nafamostat mesilate (NM)
Number of subjects: 4
Study 12798518 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard two-dose Yuzpe (levonorgestrel-ethinyl estradiol)
Number of subjects: 1682
Study 12798518 — intervention group
Group type: EXPERIMENTAL
Intervention: Norethindrone-ethinyl estradiol
Number of subjects: 1682
Study 12798518 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of Yuzpe (levonorgestrel-ethinyl estradiol)
Number of subjects: 1682
Study 12798518 — intervention group
Group type: COMPARATOR
Intervention: Single dose of Yuzpe
Number of subjects: 1682
Study 12798518 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard two-dose Yuzpe, Norethindrone-ethinyl estradiol, Single dose of Yuzpe
Number of subjects: 1682
Study 10973451 — intervention group
Group type: EXPERIMENTAL
Intervention: MnCC vaccine
Number of subjects: 45
Study 10973451 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadrivalent polysaccharide vaccine
Number of subjects: 45
Study 10973451 — intervention group
Group type: COMPARATOR
Intervention: Unimmunized control group
Number of subjects: 45
Study 8774029 — intervention group
Group type: EXPERIMENTAL
Intervention: Good Readers
Number of subjects: 108
Study 8774029 — intervention group
Group type: COMPARATOR
Intervention: Poor Readers
Number of subjects: 108
Study 1611441 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole blood transfusion
Number of subjects: 197
Study 1611441 — intervention group
Group type: EXPERIMENTAL
Intervention: Filtered blood transfusion
Number of subjects: 197
Study 1611441 — intervention group
Group type: COMPARATOR
Intervention: No blood transfusion
Number of subjects: 197
Study 6318185 — intervention group
Group type: EXPERIMENTAL
Intervention: Early immunization (DTP in the newborn nursery)
Number of subjects: 35
Study 6318185 — intervention group
Group type: COMPARATOR
Intervention: Routine immunization (DTP at 2, 4, and 6 months)
Number of subjects: 35
Study 6318185 — intervention group
Group type: COMPARATOR
Intervention: Control infants with high cord IgG anti‐LPT titers
Number of subjects: 35
Study 6318185 — intervention group
Group type: EXPERIMENTAL
Intervention: Early immunization group with lower cord IgG anti‐LPT titers
Number of subjects: 35
Study 30906944 — intervention group
Group type: COMPARATOR
Intervention: Isocaloric placebo
Number of subjects: 100
Study 30906944 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey protein supplement
Number of subjects: 100
Study 30906944 — intervention group
Group type: EXPERIMENTAL
Intervention: In-home rehabilitation + placebo
Number of subjects: 100
Study 30906944 — intervention group
Group type: EXPERIMENTAL
Intervention: In-home rehabilitation + whey protein
Number of subjects: 100
Study 30906944 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone
Number of subjects: 100
Study 30906944 — intervention group
Group type: EXPERIMENTAL
Intervention: Active intervention groups (combined)
Number of subjects: 100